At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 258 enrolled
Drug / intervention
CT-P10 +1 morebiological
Likely dose
CT-P10 375mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Randomised, Parallel-group, Active-controlled, Double-blind Study to Compare Efficacy and Safety Between CT-P10 and Rituxan in Patients With Low Tumour Burden Follicular Lymphoma
In Brief
A Phase 3 clinical trial evaluating CT-P10 and Rituxan for Follicular Lymphoma. Completed, enrolled 258 participants across 1 site.
Detailed Summary
To demonstrate that CT-P10 is similar to Rituxan in terms of efficacy as determined by overall response rate at 7 months
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFollicular Lymphoma
CountriesSouth Korea
Collaborators--
Timeline
Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedOct 2014
Enrollment StartNov 2015
Primary CompletionJan 2018
Study CompletionSep 2019
TodayJul 2026
First PostedOct 9, 2014
Enrollment StartNov 9, 2015
Primary CompletionJan 4, 2018
Study CompletionSep 4, 2019
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 11.7 years ago
Interventions
CT-P10biological
375mg/m2, IV on day1 of 4 cycles in induction period, and 12 cycles in maintenance period.
Rituxanbiological
375mg/m2, IV on day1 of 4 cycles in induction period, Rituxan for the first 6 cycles and CT-P10 for the last 6 cycles in maintenance period.